A large pre-legalization survey of over 700 Canadian cannabis users found that the vast majority of those reporting medical use also used recreationally, and this dual-motive group showed more frequent consumption, higher rates of problematic use, and greater anxiety, depression, and trauma symptoms than recreational-only users. These associations are cross-sectional and cannot determine whether cannabis is helping, harming, or simply co-occurring with psychiatric burden.

Clinicians routinely ask patients whether they use cannabis for medical or recreational purposes, but that binary framing may fundamentally mischaracterize how most people actually consume the plant. With cannabis legalization accelerating across jurisdictions, understanding who reports medical use, what that label actually means, and whether those individuals carry distinct psychiatric risk profiles is essential for effective screening and clinical counseling. If the dominant pattern is dual-motive use with limited clinical oversight, the implications for how we structure intake conversations and risk assessments are substantial.

Cannabis use patterns are frequently discussed in binary terms: medical versus recreational. However, the clinical reality appears far more complex. This cross-sectional survey, conducted in September and October 2018 in Ontario, Canada, just before national legalization, drew from a pre-existing community research registry of 1,480 valid participants. Among the 709 individuals who reported cannabis use in the prior six months, researchers classified users into three groups: recreational-only (REC, 61.4%), medical-only (MED-ONLY, 7.5%), and dual-motive medical plus recreational (MED+REC, 31.2%). The study used well-validated instruments including the CUDIT-R for problematic cannabis use, AUDIT for alcohol use, GAD-7 and PHQ-9 for anxiety and depression, and PCL-5 for trauma symptoms.

The central finding was that 80.6% of all individuals who reported any medical cannabis use also used recreationally. Medical users as a group reported significantly more frequent cannabis consumption, with daily use as the modal pattern, compared to recreational-only users whose modal pattern was less than weekly use. Medical users also scored higher on the CUDIT-R for problematic use and reported significantly greater anxiety, depression, and trauma symptom severity. Critically, only 23.4% of self-identified medical users held formal health-professional authorization. The dual-motive subgroup showed higher rates of daily use and greater alcohol and tobacco consumption than exclusive medical users. The authors appropriately note that the cross-sectional design and convenience sample, which was enriched with emerging adults and high-risk drinkers from a prior study recruitment wave, preclude causal conclusions and limit generalizability to the broader Canadian population.

This study gets something important right: the medical-versus-recreational binary is a policy fiction that does not reflect how most cannabis consumers actually behave. When 80% of people who say they use cannabis medically also report recreational use, the clean categories we rely on in clinical documentation and regulatory frameworks start to look quite fragile. The elevated psychiatric symptom burden in medical users is not surprising, as people in distress often reach for relief before and outside of formal medical channels, and that observation by itself tells us nothing about whether cannabis is helping, hurting, or simply present.

In my own practice, I never accept “medical” or “recreational” as a complete answer. I ask patients specifically what symptoms they are targeting, what their consumption frequency and pattern look like, whether they have noticed tolerance or escalation, and whether other substances are in the picture. The finding that only a quarter of self-identified medical users had any clinical authorization reinforces what I see daily: patients are making their own treatment decisions, and our job is to meet them where they are with structured guidance rather than pretending the label alone tells us what we need to know.

For clinicians, this study sits in the descriptive epidemiology phase of the research arc, providing a pre-legalization snapshot against which post-legalization trends can eventually be measured. It confirms what several earlier studies have suggested: the boundaries between medical and recreational cannabis use are porous, and self-reported medical use often occurs without clinical oversight. This aligns with prior findings from the National Epidemiologic Survey on Alcohol and Related Conditions in the United States and with Canadian Cannabis Survey data showing that medical users tend to consume more frequently and report more health concerns. What this study adds is the granularity of the dual-motive characterization and the psychiatric symptom profile attached to it.

From a pharmacological and safety standpoint, the co-occurring alcohol and tobacco use in the dual-motive group warrants particular clinical attention. Heavy polysubstance use complicates dose-response relationships, hepatic metabolism (especially relevant for CBD and THC interactions with CYP enzymes), and psychiatric symptom interpretation. The finding that dual-motive users disproportionately used cannabis for psychiatric conditions, including anxiety, depression, and PTSD, while simultaneously showing higher problematic-use scores underscores the need for careful screening. Clinicians should consider integrating validated instruments like the CUDIT-R into routine intake for any patient reporting cannabis use, regardless of how they label their consumption motive.